Eumentis Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Mezzanine
- Latest Deal Amount
-
$765K
- Investors
-
8
Eumentis Therapeutics General Information
Description
Developer of novel therapies designed to treat neuro problems and diseases. The company synthesizes knowledge about established effective therapies with the latest insights into brain function and focuses on neurodevelopmental and neurodegenerative diseases by translating cutting-edge science into patient recovery, enabling the healthcare industry with better biopharmaceutical treatments.
Contact Information
Website
www.eumentistx.comCorporate Office
- 440 Stevens Avenue
- Suite 200
- Solana Beach, CA 92075
- United States
Corporate Office
- 440 Stevens Avenue
- Suite 200
- Solana Beach, CA 92075
- United States
Eumentis Therapeutics Timeline
Eumentis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Mezzanine | 26-Jun-2024 | $765K | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series B) | Completed | Generating Revenue | ||||
| 5. Early Stage VC | 17-Mar-2023 | Completed | Generating Revenue | |||
| 4. Grant | 08-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 08-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 27-Oct-2020 | $3.9M | $3.9M | Completed | Pre-Clinical Trials | |
| 1. Grant | 13-Feb-2020 | $2M | Completed | Pre-Clinical Trials |
Eumentis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Eumentis Therapeutics Patents
Eumentis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021231582-A1 | Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia | Inactive | 12-May-2020 | ||
| EP-4121403-A1 | Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections | Inactive | 19-Mar-2020 | ||
| EP-4121403-A4 | Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections | Inactive | 19-Mar-2020 | ||
| US-20230218548-A1 | Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections | Inactive | 19-Mar-2020 | ||
| WO-2021188864-A1 | Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections | Inactive | 19-Mar-2020 | A61P11/00 |
Eumentis Therapeutics Signals
Eumentis Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| United States Department of War | Government | |||
| K2X | Venture Capital | Minority | ||
| Rivermount VC Fund | Venture Capital | Minority | ||
| Joyance Partners | Venture Capital | Minority | ||
| Life Science Angels | Angel Group | Minority |
Eumentis Therapeutics FAQs
-
When was Eumentis Therapeutics founded?
Eumentis Therapeutics was founded in 2019.
-
Where is Eumentis Therapeutics headquartered?
Eumentis Therapeutics is headquartered in Solana Beach, CA.
-
What is the size of Eumentis Therapeutics?
Eumentis Therapeutics has 8 total employees.
-
What industry is Eumentis Therapeutics in?
Eumentis Therapeutics’s primary industry is Drug Discovery.
-
Is Eumentis Therapeutics a private or public company?
Eumentis Therapeutics is a Private company.
-
What is Eumentis Therapeutics’s current revenue?
The current revenue for Eumentis Therapeutics is .
-
How much funding has Eumentis Therapeutics raised over time?
Eumentis Therapeutics has raised $13.7M.
-
Who are Eumentis Therapeutics’s investors?
United States Department of War, K2X, Rivermount VC Fund, Joyance Partners, and Life Science Angels are 5 of 8 investors who have invested in Eumentis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process